13F Holdings
中文EN

MIST Milestone Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1408443 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-68.7%
TTM EPS YoY6.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,370.6%
ROA-78.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets103.8%
Debt / equity—
Current ratio6.27x
Interest coverage-7.62x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-16.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$18.11M$14.36M$31.05M$39.83M$38.67M
SG&A expense$17.27M$16.74M$15.93M$15.72M$12.40M
Operating income-$62.14M-$42.10M-$61.10M-$59.64M-$43.07M
Interest expense$3.84M$3.58M$2.55M——
Pretax income-$63.06M-$41.52M-$59.69M-$58.39M-$42.85M
Net income-$63.06M-$41.52M-$59.69M-$58.39M-$42.85M
EBITDA-$62.03M-$42.00M-$61.01M-$59.55M-$42.98M
EPS (basic)-0.75-0.67-1.39-1.38-1.02
EPS (diluted)-0.75-0.67-1.39-1.38-1.02
Balance sheet
Cash & equivalents$73.05M$25.31M$13.76M$7.64M$114.14M
Short-term investments$32.91M$44.38M$52.24M$56.95M$0
Inventory$648,000————
Current assets$111.92M$73.93M$73.03M$71.80M$118.92M
PP&E, net$511,000$197,000$277,000$257,000$215,000
Total assets$113.56M$75.50M$75.23M$74.48M$119.85M
Current liabilities$13.98M$8.13M$7.23M$6.14M$6.78M
Long-term debt$57.19M$53.35M$49.77M——
Total debt$57.19M$53.35M$49.77M——
Total liabilities$71.79M$62.35M$58.45M$8.13M$7.25M
Shareholders' equity$41.77M$13.15M$16.77M$66.35M$112.60M
Net debt-$15.86M$28.04M$36.01M——
Shares outstanding106.24M53.35M33.48M34.29M29.90M
Cash flow statement
Operating cash flow-$49.04M-$28.85M-$46.42M-$52.47M-$33.22M
Capital expenditure$302,000$33,000$112,000$272,000—
Free cash flow-$49.34M-$28.88M-$46.54M-$52.74M—
Investing cash flow$11.25M$8.28M$4.76M-$57.12M$70.00M
Financing cash flow$85.53M$32.12M$47.79M$3.09M$5.05M
Depreciation & amortization$114,000$105,000$92,000$89,000$93,000
Stock-based compensation$7.46M$5.78M$9.53M$9.05M$7.28M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.